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A phase 1b randomised, placebo-controlled trial of nabiximols
cannabinoid oromucosal spray with temozolomide in patients
with recurrent glioblastoma
Chris Twelves 1,2, Michael Sabel3, Daniel Checketts4, Sharon Miller4, Bola Tayo4, Maria Jove1, Lucy Brazil5,
Susan C. Short 1,2 on behalf of the GWCA1208 study group
BACKGROUND: Preclinical data suggest some cannabinoids may exert antitumour effects against glioblastoma (GBM). Safety and
preliminary efficacy of nabiximols oromucosal cannabinoid spray plus dose-intense temozolomide (DIT) was evaluated in patients
with first recurrence of GBM.
METHODS: Part 1 was open-label and Part 2 was randomised, double-blind, and placebo-controlled. Both required individualised
dose escalation. Patients received nabiximols (Part 1, n= 6; Part 2, n= 12) or placebo (Part 2 only, n= 9); maximum of 12 sprays/
day with DIT for up to 12 months. Safety, efficacy, and temozolomide (TMZ) pharmacokinetics (PK) were monitored.
RESULTS: The most common treatment-emergent adverse events (TEAEs; both parts) were vomiting, dizziness, fatigue, nausea and
headache. Most patients experienced TEAEs that were grade 2 or 3 (CTCAE). In Part 2, 33% of both nabiximols- and placebo-treated
patients were progression-free at 6 months. Survival at 1 year was 83% for nabiximols- and 44% for placebo-treated patients (p=
0.042), although two patients died within the first 40 days of enrolment in the placebo arm. There were no apparent effects of
nabiximols on TMZ PK.
CONCLUSIONS: With personalised dosing, nabiximols had acceptable safety and tolerability with no drug–drug interaction
identified. The observed survival differences support further exploration in an adequately powered randomised controlled trial.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: Part 1– NCT01812603; Part 2– NCT01812616.
British Journal of Cancer https://doi.org/10.1038/s41416-021-01259-3
BACKGROUND
Glioblastoma (GBM) is the most common malignant primary brain
tumour in adults, with an estimated incidence of 3.2 per 100,000,
and 5-year survival rate of <6%.1 GBM is incurable, but current
optimal therapy involves maximal debulking surgery followed by
local high-dose radiotherapy and temozolomide (TMZ) che-
motherapy.2 With this treatment median overall survival (OS) is
14.6 months for patients well enough to undergo treatment.
Tumour recurrence occurs in almost all patients,3 usually
6–9 months after treatment. Following recurrence, median
survival falls to 1.0–10.8 months,4,5 and there is no current
standard of care for such patients.6
Despite preclinical and clinical efforts, improving outcomes for
patients with GBM has proved challenging. Additional therapy
with tumour-treating fields (TTF), which alternate electric fields at
specific frequencies and intensities to disrupt mitosis in cancer
cells, may impact OS,7–9 but has not become standard of care. In
addition, subgroups of GBM patients with O6-methylguanine DNA
methyltransferase (MGMT) promoter methylation have been
shown to have a better prognosis and benefit from more
aggressive initial therapy with TMZ and lomustine.10–12 As such,
while recent advances in molecular pathology may allow for more
individualised treatment in some patients, many patients with
GBM do not benefit, and new treatments are urgently required.
Phytocannabinoids occur naturally in cannabis plants and have
been used medicinally for centuries for a variety of purposes.13 Δ9-
tetrahydrocannabinol (THC) is the major psychoactive constituent
in cannabis, and cannabidiol (CBD) is the major non-psychoactive
constituent; these are the most studied naturally occurring
cannabinoids. In studies in animals and humans, THC can exert
analgesic, antispasmodic, antitremor, anti-inflammatory, appetite
stimulant and antiemetic properties.14 In studies in animals and
humans, CBD can exert antiepileptic, neuroprotective, anti-
inflammatory, antipsychotic, antidystonic and antiemetic
effects.15–19
Unlike THC, CBD has no physiologically relevant effect on the
cannabinoid receptors, CB1 and CB2, but targets other G protein-
coupled receptors such as GPR12, GPR6, GPR3, GPR55 and 5-HT1A,
as well as transient receptor potential vanilloid receptors, TRPV1
and TRPV2.20–25 THC is a partial CB1 and CB2 receptor agonist.
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Activation of CB1 and CB2 receptors exerts a variety of down-
stream signalling effects, with diverse consequences on cellular
biology and functions.27
GBM tumours express both CB1 and CB2,
28 with high-grade
tumours expressing high levels of CB2. This altered expression of
cannabinoid receptors in GBM led to the hypothesis that
cannabinoids may exhibit antitumour effects. Numerous in vivo
studies have found that administration of CBD and THC reduced
tumour growth in animal models of glioma (reviewed by Rocha
et al., 201429). These effects are thought to be mediated by
induction of cell death (via apoptosis or cytotoxic autophagy),
inhibition of cell proliferation, and antiangiogenic effects
(reviewed by Dimitru et al., 201830). Specific to GBM, the
combined administration of THC and TMZ exerts strong anti-
tumoural effects in glioma xenografts, an effect maintained in
tumours resistant to TMZ treatment.31 Furthermore, treatment
with TMZ and submaximal doses of THC and CBD has strong
antitumoural activity both in TMZ-sensitive and TMZ-resistant
tumours.31
The first pilot trial to investigate the effects of intracranial THC
(100 mg mL−1 in ethanol) in patients with recurrent GBM in
2006 showed a reduction in tumour cell proliferation in two of
nine patients.32 However, this evidence of promising antineo-
plastic activity of THC and CBD in GBM has not yet been further
assessed. Sativex® ([nabiximols oromucosal spray] GW Research
Ltd [GW], Cambridge, United Kingdom [UK]) is a complex
botanical formulation containing THC, CBD, and additional
cannabinoid and non-cannabinoid components. Nabiximols is
approved for symptom improvement in patients with moderate
to severe spasticity due to multiple sclerosis who have not
responded adequately to other antispasticity medications in
>25 countries but not the United States. In this trial, we
investigate the safety and tolerability of nabiximols oromucosal
spray in combination with dose-intense TMZ (DIT) in patients
with recurrent GBM, as reflected by the frequency and severity
of treatment-emergent adverse events (TEAEs: adverse events
with onset or worsening after administration of the first dose
of study drug, irrespective of relatedness to treatment). In
addition, secondary efficacy outcomes, specifically patients’
progression-free survival at 6 months (PFS6) and OS at 1 year
(i.e. the planned end of treatment), as well as the effects of
nabiximols on TMZ and metabolite pharmacokinetics (PK), were
assessed.
METHODS
Compliance with ethical standards
This trial was conducted in accordance with International Council
for Harmonisation Good Clinical Practice guidelines and ethical
principles that have their origin in the Declaration of Helsinki. The
protocol was approved by the relevant Institutional Review Board
or Independent Ethics Committee at each site, and all patients
provided written informed consent. The trial protocol is registered
on the ClinicalTrials.gov website (Part 1: NCT01812603; Part 2:
NCT01812616).
Stopping rules
The trial could be terminated by the sponsor, primarily for safety,
but also for other unanticipated reasons. Stopping rules for
individual sites and patients are described in Supplemental
Materials.
Patients
Eligible patients were ≥18 years old with a histopathologically
confirmed diagnosis of GBM (World Health Organization classifica-
tion [version 200733]) and evidence of first disease progression,
following radiotherapy and first-line chemotherapy with TMZ.
Patients had a ≥60% Karnofsky Performance Scale (KPS) status
and, if taking steroids, were on a stable or reducing dose. All
patients received standard of care (i.e. 6 weeks radiation therapy
with concomitant TMZ then adjuvant TMZ).
Trial design
This was a multisite, sequential, 2-part, Phase 1b trial. Patients
were enrolled into Part 1 (open-label) or Part 2 (randomised,
double-blind, placebo-controlled; 1:1 allocation), both of which
followed the same schedule of visits and procedures (see
Supplemental Fig. 1). Patients enrolled in Part 1 were not
permitted to enter Part 2. The trial was conducted at 10 sites (7
UK; 3 Germany) between January 2014 and August 2016.
Nabiximols and placebo dosing
Due to the high degree of interpatient variability in the PKs and
pharmacodynamics of nabiximols,34,35 the dosing regimen was an
individualised dose of 3–12 sprays/day, based on a dose-ranging
trial that showed a favourable risk/benefit profile in patients with
chronic pain.36 In both trial parts, treatment started with a single
spray in the evening of Day 1, with gradual individualised titration
of nabiximols or placebo (Part 2 only) by 1 additional spray/day, to
a maximum dose based upon tolerability of up to 12 sprays/day
(30 mg CBD and 32.4 mg THC). If a patient experienced
unacceptable side effects during titration, the dose was reduced
until the side effects resolved. Patients settled on a personalised
maximum tolerated dose (MTD) within 14 days of their first dose
of nabiximols or placebo and continued at that dose for the
remainder of the trial. If patients experienced unacceptable side
effects in the period following titration, they were advised to
reduce their dose slightly until these resolved.
Part 1. Six patients participated in Part 1 (open-label) in two
cohorts of three patients each. All received nabiximols and DIT
with TEAEs recorded according to the common terminology
criteria for adverse events (CTCAE version 4.03).
A safety review team (SRT) assessed the progress of Part 1
(open-label) of the trial to determine whether the second cohort
in Part 1 and subsequently Part 2 could commence, as described
in Supplemental Materials.
Part 2. Following approval from the SRT, 21 patients were
randomised to receive DIT plus nabiximols or placebo using a 1:1
allocation ratio.
Trial procedures
Patients commenced DIT on Day-7 (85.0 mg/m2 daily) and
returned to trial sites on Day 1 when nabiximols (Parts 1 and 2)
or placebo (Part 2 only), was dispensed. Patients titrated
nabiximols/placebo as described above. Patients were instructed
to take nabiximols or placebo at their personalised MTD for 1 year
or until trial withdrawal; individual stopping rules are given
in Supplemental Materials. DIT was administered orally for 13
cycles each of 28 days, i.e. up to 1 year with dosing on Days 1–21
of each cycle followed by 7 days off drug; the daily dose could be
reduced to 70% and subsequently 50% if patients experienced
DIT-related haematological TEAEs.
Pharmacokinetics. The effects of the addition of nabiximols to
TMZ on the PK of TMZ and its metabolite, 4-amino-5-imidazole-
carboxamide (AICA), were investigated. Blood sample collection,
processing, and bioanalysis methods are described in Supplemen-
tal Materials.
PK parameters were derived by non-compartmental analysis
using WinNonlin® version 6.3 and included area under the plasma
concentration-time curve to 6 h (AUC0-6h) and to the last timepoint
(AUC0-t), maximum plasma concentration (Cmax), terminal (elim-
ination) half-life (t½), time to maximum plasma concentration
(tmax), apparent oral clearance after oral administration (CL/F) and
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apparent volume of distribution after non-intravenous adminis-
tration (Vz/F).
Randomisation and blinding
For Part 2 only (randomised), a 1:1 treatment allocation schedule
with balanced randomly permuted blocks using a computer-
based algorithm was produced independently; see Supplemental
Materials for further information. Patients, investigators and the
sponsor were blinded to the allocation and remained so until trial
closure.
Outcome measures
The primary objective of this trial was to investigate the
tolerability and safety of nabiximols spray in patients with
recurrent GBM, as indicated by the frequency and severity of
TEAEs. Secondary objectives included investigating the prelimin-
ary efficacy of nabiximols compared with placebo, determined by
PFS6 (magnetic resonance image [MRI] scans were performed for
tumour assessment as per international consensus for both
practice and trials via the revised assessment in neuro-oncology
[RANO] criteria [additional MRI information can be found
in Supplemental Materials])3,37 and survival at 1 year. Other
secondary objectives were to determine any effects of nabiximols
on TMZ PK.
Unplanned (post-hoc) analyses
Since the trial was not designed to investigate survival differences,
a post-hoc 2-year survival analysis was undertaken to further
probe the effect of treatment in individual patients using the
European Organisation for Research and Treatment of Cancer
(EORTC) prognostic calculator of survival in patients with recurrent
GBM.38 This calculated a predicted median (and range) OS for
each trial patient that was compared with the actual outcome
data. Patients were followed up for up to 27.5 months.
Statistical analysis
Sample size. This was an exploratory Phase 1b trial with no
formal sample size calculation. Part 1 (open-label) planned to
enrol six patients and Part 2 (randomised) planned to enrol 20
patients.
Statistical methods. All hypotheses were tested at a 5% level of
nominal statistical significance using a two-sided test. Due to the
exploratory nature of this trial, no adjustments were made for
multiple testing; Part 2 was randomised to ensure balance and
limit bias in the safety comparisons. The safety analysis set was
used for the analyses of all outcome parameters. Additional
information can be found in Supplemental Materials.
RESULTS
Disposition of patients
Part 1. Six patients enrolled in Part 1 (open-label), received
nabiximols spray as planned and were included in the safety
analysis.
The mean age of patients was 50.2 years (median 57, range:
28–67 years) and the mean time to diagnosis of recurrent GBM
from initial diagnosis was 18.9 months (median 20.2 months,
range: 8.6‒25.7 months). Mean time to patients entering the trial
after the diagnosis of recurrence was 1 month (median 1.1 months,
range: 0.5‒2.2 months). The median KPS at baseline was 90%
(Supplemental Table 1); the proportion of patients in each KPS
category is presented in Fig. 1.
Three patients (50.0%) came off study due to Grade 1 and 2
TEAEs (one due to lethargy, dizziness and fatigue, one due to
nausea, diarrhoea and vomiting and one due to depressed mood),
and three (50.0%) because of disease progression after an overall
mean of 4.13 months for the six patients that came off study
(Fig. 2a). There were no deaths during nabiximols treatment; three
patients, however, subsequently died after coming off study.
Part 2. Twenty-one patients were randomised in Part 2 of the
trial; 12 received nabiximols and nine received placebo, and all
were included in the safety analysis.
The mean age was 57.8 years in both treatment groups
(nabiximols median 59, range: 39–72 years; placebo median 57,
range: 43–71 years). In the nabiximols and placebo treatment
arms, 41.7% and 88.9% of patients were male, respectively. The
mean time to diagnosis of recurrent GBM from initial diagnosis
was 23.7 months (median 22.9 months, range: 3.1‒43.4 months;
nabiximols group) and 21.7 months (median 19.6 months, range:
6.2‒55.7 months; placebo group). Mean time to patients entering
the trial after the diagnosis of recurrence was 1.6 months (median
0.8 months, range: 0.4‒6.8 months; nabiximols group) and
0.8 months (median 0.8 months, range: 0.1‒2.0 months; placebo
group). The median KPS at baseline was 90% for both patient
groups (Supplemental Table 1); the proportion of patients in each
























Part 1 (open-label): Nabiximols Part 2 (randomised): Nabiximols Part 2 (randomised): Placebo
Karnofsky Performance Scale (%)
60 70 80 90 100 60 70 80 90 100 60 70 80 90 100
Fig. 1 Proportion of patients in each KPS category at baseline. KPS Karnofsky Performance Scale.
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In Part 2, 17 patients came off study (11 nabiximols and 6
placebo) and 4 patients (1 nabiximols and 3 placebo) completed
the trial (~1 year of treatment) (Fig. 2b). Seven (41.2%) patients
came off study due to disease progression (3 taking placebo; 4
taking nabiximols, 1 of whom also listed TMZ intolerance as a
reason for withdrawal), 5 (29.4%) as a result of an investigator
decision (1 considered too ill to continue study medication or
chemotherapy [the patient was hospitalised due to a recurrent
urinary infection which lasted for 3 months] and 4 due to disease
progression), 3 (17.6%) due to TEAEs (1 due to concentration
impairment and urinary incontinence and 2 due to disease
progression) and 2 (11.8%) due to withdrawal of consent (1 due to
a patient feeling too unwell to continue and 1 due to a patient
feeling as though they were experiencing toxicity to the study
medication and their concomitant medication [although no
associated TEAEs were reported], requiring withdrawal per
protocol).
Seven (33.3%) patients died during Part 2, 5 (55.6%) taking
placebo and 2 (16.7%) taking nabiximols. Prior to death, all
patients had come off study due to disease progression except
for one patient taking nabiximols who came off study due
to TEAEs.
Drug exposure
Part 1. In Part 1, once titration had been completed and a stable
personalised nabiximols dose established, patients took a mean of
6 sprays/day (range: 3.3–12 sprays/day). The mean duration of
exposure was 16 weeks (median 15.1 weeks, range: 3.9–31 weeks).
The mean dose of DIT was 146.6 mg (median 145.0 mg, range:
93.8–195.0 mg) or 77.8 mg/m2 (median 82.9 mg/m2, range:
49.2–85.4 mg/m2) relative to body surface area.
Part 2. Patients taking nabiximols administered a mean of
7.5 sprays/day after the titration period (range: 2.0–12 sprays/
day); only one patient took fewer than the recommended
minimum daily dose. The mean duration of exposure to nabiximols
was 24.9 weeks (median 22.1 weeks, range: 7.1–50.9 weeks).
The mean dose of DIT was 154.7 mg (median 153.9 mg, range:
117.5–185.0 mg) or 81.2 mg/m2 (median 83.3 mg/m2, range:
56.2–87.3 mg/m2) relative to body surface area.
Patients taking placebo administered a mean of 10 sprays/day
after the titration period (range: 7.0–12 sprays/day) and the mean
duration of exposure was 23.6 weeks (median 19.1 weeks, range:
1.9–51.3 weeks). The mean dose of DIT was 165.6mg (median
170.0mg, range: 125.0–195.0 mg), with a mean dose relative to
Assessed for eligibility (n = 7)
Enrolled (n = 6)
Screen failure (n = 1)
Nabiximols + DIT
(n = 6)
Completed (n = 0)
Safety analysis set
(n = 6)
Withdrawn (n = 6)
Adverse event (n = 3)
Met protocol-defined







Randomised (n = 21)
Screen failure (n = 5)
Nabiximols + DIT
(n = 12)
Completed (n = 1)
Safety analysis set
(n = 12)
Withdrawn (n = 6)
Adverse event (n = 2)
Met protocol-defined 
withdrawal criteria (n = 3)
Withdrawn by 





Completed (n = 3)
Safety analysis set
(n = 9)
Withdrawn (n = 11)
Adverse event (n = 1)
Withdrew consent (n = 2)
Met protocol-defined 
withdrawal criteria (n = 4)
Withdrawn by 
investigator (n = 4)
Follow-up
b
Fig. 2 Disposition of patients enrolled. a Trial Part 1 (open-label). b Trial Part 2 (randomised). CBD cannabidiol, THC, Δ9-tetrahydrocannabinol.
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body surface area of 81.1mg/m2 (median 83.6 mg/m2, range:
63.3–86.5mg/m2).
Safety and tolerability
In both parts of the trial, the most frequent potentially clinically
significant laboratory results were either low white blood cell
counts or elevated liver enzymes. Abnormal laboratory results,
reported as TEAEs, were consistent with the patients’ underlying
disease and treatment with TMZ. There were no unexpected
findings on physical examination, electrocardiogram, or vital signs.
Compared with previous experience in nabiximols studies, no new
safety concerns were identified.
Part 1. There were no fatalities during Part 1. Three (50.0%)
patients experienced TEAEs, which led to discontinuation and
three (50.0%) discontinued due to disease progression. TEAEs
leading to discontinuation differed between patients and the
maximal severity was CTCAE grade 2.
Table 1 reports TEAEs experienced by ≥2 patients and their
maximal severity. Fatigue, dizziness, headache, vomiting and
nausea were the most frequently observed TEAEs. Fatigue,
dizziness and headache are commonly associated with GBM
(fatigue and dizziness are also common side effects of nabiximols),
and the incidence of nausea and vomiting is expected with
chemotherapy and a recognised side effect of nabiximols. The
serious AEs observed were neoplasm progression for one patient
and intracranial haemorrhage (grade 1) and focal seizures (grade
1) for another; the patient who experienced intracranial haemor-
rhage had no changes to study medication at the time of the
event.
Part 2. Two patients (22.2%) in the placebo group and none in
the nabiximols group died of disease progression by the time of
the last planned follow-up.
The rates of TEAEs leading to discontinuation were similar in
both treatment groups (two patients in each group [16.7%
nabiximols vs. 22.2% placebo]). One patient in each group
discontinued due to disease progression. The TEAEs leading to
withdrawal in the remaining two patients were disturbance in
attention, vomiting, ataxia and urinary incontinence for the
placebo patient and urinary tract infection for the nabiximols
patient.
Table 1 reports TEAEs experienced by ≥2 patients and their
maximal severity. The incidence of TEAEs was similar in both
treatment arms. Vomiting, dizziness, nausea and fatigue were the
most frequently observed TEAEs. Patients taking nabiximols
reported more severe TEAEs and had a higher incidence of
serious TEAEs. Four patients taking nabiximols experienced serious
TEAEs as follows: urinary tract infection for one patient, lower
respiratory tract infection and anaemia for another, campylobacter
gastroenteritis and asthenia for a third, and faecaloma for the
fourth patient. Two patients in the placebo group experienced
serious TEAEs as follows: neoplasm progression and pulmonary
embolism for the first patient and neoplasm progression for the
second patient.
Supplemental Table 2 presents the maximum toxicities of TEAEs
experienced by each patient and any action taken as a result.
Exploratory efficacy
Progression-free survival at 6 months. In Part 1, one (16.7%)
patient was classified as progression-free at six months, four
(66.7%) patients had progressed, and response status was
unknown for one (16.7%) patient.
In Part 2, in the nabiximols group, four (33.3%) patients were
classified as progression-free at six months, seven (58.3%) patients
had progressed, and response status was unknown for one (8.3%)
patient. In the placebo group, three (33.3%) patients were
classified as progression-free at six months, five (55.6%) patients
had progressed, and response status was unknown for one
(11.1%) patient.
1-year survival analysis. In Part 1, at 1 year three of six (50.0%)
patients taking nabiximols were alive.
In Part 2, at 1 year 10 of 12 (83.3%) patients taking nabiximols
were alive vs. four of nine (44.4%) patients taking placebo;
although the trial was not statistically powered to compare OS,
this difference in 1-year survival rate favouring nabiximols
achieved nominal statistical significance (p= 0.042, log-rank test;
Fig. 3).
Post-hoc 2-year survival analyses. Two-year survival data from
elective follow-up of all patients (Parts 1 and 2) for a maximum of
Table 1. All-causality treatment-emergent adverse events reported in
≥2 patients (safety analysis set).
Part 1 (open-label)
TEAE Nabiximols N= 6 CTCAE Gradea
Number of patients (%)
Fatigue 4 (66.7) 2
Dizziness 3 (50.0) 1
Headache 3 (50.0) 2
Nausea 3 (50.0) 1
Vomiting 3 (50.0) 2
Vision blurred 2 (33.3) 2
Weight increased 2 (33.3) 1
Amnesia 2 (33.3) 1
Aphasia 2 (33.3) 1
Lethargy 2 (33.3) 2
Somnolence 2 (33.3) 1
Non-cardiac chest pain 2 (33.3) 3














Vomiting 9 (75.0) 1 1 (11.1) 1
Dizziness 8 (66.7) 2 2 (22.2) 1
Nausea 7 (58.3) 1 1 (11.1) 1
Fatigue 5 (41.7) 2 5 (55.6) 2
Headache 4 (33.3) 3 1 (11.1) 1
Constipation 4 (33.3) 3 0 N/A
Dry mouth 2 (16.7) 1 1 (11.1) 1
Thrombocytopenia 2 (16.7) 2 0 N/A
Feeling abnormal 2 (16.7) 1 0 N/A
Oedema peripheral 2 (16.7) 3 0 N/A
Cystitis 2 (16.7) 2 0 N/A
Urinary tract infection 2 (16.7) 4 1 (11.1) 1
Lethargy 2 (16.7) 1 0 N/A
Cough 2 (16.7) 1 0 N/A
Neoplasm progression 1 (8.3) 3 2 (22.2) 5
Urinary incontinence 0 N/A 2 (22.2) 2
TEAE treatment-emergent adverse event.
aMaximal severity in any patient who experienced the TEAE.
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27.5 months outside the protocol were also available, with OS at 2
years of 50% for patients treated with nabiximols and 22% for
those treated with placebo (nominal p= 0.134, log-rank test).
Median OS was estimated at 21.8 months (95% confidence
interval [CI]: 10.0, not calculable [NC] as not enough events) for the
nabiximols group and 12.1 months (95% CI: 1.18, NC) for the
placebo group.
Post-hoc analysis using the EORTC prognostic calculator of
survival for patients with recurrent GBM was used to calculate a
predicted median (range) OS for each trial patient at enrolment
that was then compared with the actual outcome for all patients
based upon their 1-year survival (Supplemental Table 3 [Part 2];
Supplemental Table 4 [Part 1]).
In Part 2 of the trial, 10 (83.3%) patients taking nabiximols had
OS that exceeded their EORTC-predicted median survival time;
seven (58.3%) exceeded the upper range of their EORTC-predicted
median survival time (Supplemental Table 3). Only one (8.3%)
patient taking nabiximols survived for less than their lowest range
predicted survival time.
In contrast, only three (33.3%) patients in the placebo group
had OS that exceeded their EORTC-predicted median survival, one
(11.1%) patient had OS as per their EORTC-predicted median
survival, and only one (11.1%) patient exceeded the upper range
of their EORTC-predicted median survival time. One (11.1%)
patient was still alive after 25.5 months, so it was unknown
whether they would exceed the upper range predicted
(38.9 months) during extended follow-up. Two (22.2%) patients
taking placebo who died during the trial had OS that fell within
their predicted ranges and two (22.2%) patients had an OS time
that fell short of the lowest time predicted. One (11.1%) patient,
who discontinued the trial due to rapid progression and later died,
could not have a predicted survival time defined by the EORTC
tool (Supplemental Table 3).
Pharmacokinetics
Patients excluded from the PK analysis are described in Supple-
mental Materials. In Parts 1 and 2, there was no effect on TMZ or
AICA exposure (Cmax and AUC0-t), or tmax when patients took
DIT alone (Day 1) compared to co-administration with nabiximols
(Day 36) (Supplemental Table 5 and Supplemental Table 6,
respectively).
Statistical analysis was performed for Part 2 only. For TMZ, the
ratio of geometric least squares (LS) means (95% CI) between the
nabiximols and placebo groups for change in TMZ neared 1 for all
exposure parameters, and was 1.02 (0.78, 1.33) for Cmax, 0.95 (0.82,
1.11) for AUC0-6h and 0.91 (0.78, 1.05) AUC0-t.
For AICA, the ratio of geometric LS means (95% CI) between the
nabiximols and placebo groups for change in TMZ was slightly
greater than 1 for all but AUC0-t, and was 1.66 (0.70, 3.89) for Cmax,
1.21 (0.75, 1.95) for AUC0-6h and 1.00 (0.64, 1.57) for AUC0-t.
DISCUSSION
This Phase 1b trial aimed to assess primarily the safety and
tolerability and secondarily the efficacy of nabiximols in patients
with recurrent GBM. In the absence of an accepted standard of
care for this population and no known conventional dosing
regimen for DIT, a DIT regimen of 85 mg/m2/day was chosen as
the backbone chemotherapy since resistance to temozolomide is
partially mediated by MGMT, and MGMT may be depleted by
prolonged temozolomide administration. A DIT regimen may,
therefore, overcome resistance39 and was considered an optimal
comparator. Results showed the feasibility of a personalised
dosing regimen of nabiximols in combination with DIT in patients
with recurrent GBM, as per the primary outcome measures
informing safety and tolerability. Additionally, the secondary
outcomes of efficacy, and the effect of nabiximols on TMZ PK
were assessed. Although both Parts 1 and 2 of the trial suggested
increased efficacy, as defined by survival time, in patients treated
with adjuvant nabiximols, any conclusions on efficacy are limited
by the small sample size and potentially confounding factors that
may differ between cohorts. PK outcomes suggested there was no
significant effect of nabiximols on the systemic exposure of TMZ
when administered as part of DIT.
There is a growing body of preclinical research that supports the
antitumour activity of cannabinoids, including THC and CBD.29,30
Treatment with TMZ and submaximal doses of THC and CBD
produced a strong antitumoural action in both TMZ-sensitive and

































Fig. 3 Kaplan–Meier survival curves (randomised safety analysis set). Patients who did not die during the 1-year analysis period were
censored and marked by a +. If a patient was alive at the end of treatment, then the end of treatment visit was the date at which they were
censored. Otherwise if a patient withdrew, they were censored at the date of the survival status review. If a patient was lost to follow-up then
they were censored at the last known visit date. The number of patients at risk at a given timepoint was the number still alive or who had not
been censored.
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TMZ-resistant GBM xenografts.31 The first pilot trial to evaluate the
safety and efficacy of THC administered intratumourally in nine
patients with recurrent GBM showed a good safety profile and
possible antiproliferative effects of THC in two patients; however,
effects on survival were unclear.32 Cerebral oedema was experi-
enced by all patients in that trial in the early postoperative period
following craniotomy. Additionally, there were mild, transient
episodes of bulimia, hypothermia and euphoria in a single
patient.32
The primary aim of the present trial was to analyse the safety
and tolerability of personalised dosing of nabiximols oromucosal
spray when co-administered with DIT. It should be noted that the
safety findings from this study might not translate to a less fit
patient population. The incidence of TEAEs in this trial was high in
both nabiximols- and placebo-treated patients, for reasons
discussed above. In Part 1 (open-label), most TEAEs were mild
(CTCAE grade 1) or moderate (grade 2), the most frequently
reported being fatigue, dizziness, headache, and vomiting. There
were no grade 4 TEAEs.
In Part 2 (randomised), the incidence of TEAEs was higher in the
nabiximols group than the placebo group, and those taking
nabiximols reported more severe TEAEs and had a higher
incidence of serious TEAEs. The two deaths during the trial
occurred in the placebo group and were due to disease
progression. This should be considered in the context of the
sample overall sample size (n= 21) of Part 2 of the trial, with 12
patients receiving nabiximols and 9 placebo.
The incidence of TEAEs in this trial was higher than in previous
Phase 3 randomised clinical trials of nabiximols as an adjunct
analgesic in patients with advanced cancer (68‒72% in
nabiximols-treated patients and 64‒66% in placebo-treated
patients34,35). Given the nature of the present indication, many
neurological and other TEAEs were considered related to the
patient’s underlying GBM. Furthermore, the duration of treatment
in the current trial was 1 year compared with 5‒7 weeks in
previous Phase 3 trials.34,35 Finally, patients in the current trial
received concomitant chemotherapy, which was precluded in
previous Phase 3 trials. Therefore, the patient population and
treatment regimen were different from other Phase 3 trials and
may explain, in part, why there were more TEAEs in the current
Phase 1b trial.
Specific attribution of TEAEs is complicated by the clinical
presentation of GBM, the natural history of the disease, and
concomitant administration of cytotoxic chemotherapy. Due to
the palliative nature of GBM treatments, and the lack of
therapeutic agents that are effective with a potentially acceptable
TEAE frequency and severity profile, the results of this trial could
support further clinical trials assessing the efficacy of adjuvant
nabiximols in recurrent GBM.
The exploratory assessment of efficacy was based on patients’
PFS6 and OS at 1 year (i.e. the planned end of treatment). RANO
assessments of MRI images showed no apparent effect of
nabiximols on PFS6, with the same proportion of patients (33%)
in the nabiximols and placebo groups progression-free at six
months. In Part 1 (open-label nabiximols treatment), PFS6 was
16.7%. In both trial parts, PFS6 was higher than previously
reported, whereas data pooled from 16 Phase 2 trials in 345
patients with recurrent GBM who received radiotherapy and
various pharmaceutical therapies showed a PFS6 of only 9%.36 In
Part 1 of the trial, OS at 1 year was found to be improved
compared with previously published data, which put the death
rate at ~80%.36 In Part 2 of the trial, a significant improvement in
OS was observed at 1 year in patients taking nabiximols vs.
placebo (83% vs. 44%; log-rank test, nominal p= 0.042). It is
noteworthy that the 1-year OS rates across both treatment
groups were higher than data pooled from several published
trials of other agents, where OS at 1 year in 345 patients with
recurrent GBM was only 14%.36 The high OS in our trial must be
considered carefully as it may be explained in part by the small
sample size.
On the basis of data from extended elective follow-up (to a
maximum of 27.5 months) in the small numbers of patients
originally enrolled in Part 2 (n= 21), median OS was estimated to
be longer in the nabiximols group at 21.8 months (95% CI: 10.0,
NC) vs. 12.1 months (95% CI: 1.18, NC) for placebo. This estimated
length of OS is longer than previously reported in both patients
newly diagnosed with GBM and those with recurrent GBM.8,40 A
recent Phase 3 trial analysing the impact of TTFs in 695 patients
newly diagnosed with GBM followed up patients for a median of
40 months (466 received TTFs plus TMZ; 229 received TMZ alone)
and reported median OS of 20.9 months in the TTFs plus TMZ
group and 16.0 months in the TMZ alone group.40 A Phase 3 trial
analysing the impact of TTFs in 237 patients with recurrent GBM
followed up patients for a median of 39 months (120 received TTF
alone; 117 received chemotherapy alone) and reported median OS
of 6.6 months in the TTF alone group versus 6.0 months in the
chemotherapy alone group.8 We acknowledge that these data are
from larger and more heterogenous populations than the study
population in the present study. We did not collect treatment
information after discontinuation of the study drug as part of this
study so cannot discuss the potential impact of post-trial
treatments on OS. However, there are no interventions known
to significantly improve survival after discontinuing second-line
treatment in this patient group. Moreover, as discussed above, this
Phase 1b study had a small sample size and a possible imbalance
in confounding factors between treatment groups may have
impacted the interpretation of OS data. Also, of interest in the
current trial was the trend for nabiximols-treated patients to have
an OS which often exceeded the upper range of their EORTC-
predicted survival (58% nabiximols patients vs. 11% placebo
patients [Part 2]). While this model was not specifically developed
on the basis of data from patients receiving DIT, there is no a priori
reason to believe this invalidates the model for the prediction of
survival in DIT-treated patients.
Of note, two patients in the placebo group died within 40 days
of commencing treatment in Part 2 of the trial. It cannot be ruled
out that the two patients concerned may have been predisposed
to the premature death, e.g. by virtue of their tumour biology
including unmethylated MGMT status. The lack of detailed tumour
classification and documentation of prior therapy is a notable
limitation of this trial, and the need for full characterisation in
future trials, including MGMT methylation status, is recognised.
Although there is no expectation of different outcomes between
males and females, the considerable imbalance between males
and females in this trial should be noted.
A final aim of this trial was to assess the effect of nabiximols on
the PK of TMZ and AICA, to probe for a drug–drug interaction.
There were no relevant effects of nabiximols on TMZ or AICA
exposure parameters (Cmax and AUC0-t), suggesting no clinically
important impact of nabiximols on the PK of TMZ. The impact of
TMZ on the PK of THC, CBD or their metabolites was not evaluated
in this trial.
Trial strengths and limitations
Key strengths of the trial were the individualised titration and
personalised dosing of nabiximols and the randomised, placebo-
controlled nature of Part 2. Without randomisation and placebo
control, interpretation of the OS in patients treated with
nabiximols would have been confounded.
The major limitation is that the number of patients enrolled in
Part 2 of the trial was small, and with 21 patients enrolled across
nine sites for Part 2, there was potential heterogeneity of practice
and bias in patient selection between sites. In addition, 12 patients
were assigned to nabiximols and nine to placebo during Part 2;
this imbalance was due to randomisation being stratified by site.
Therefore, although the trial was randomised, it is possible some
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imbalance between patients in the nabiximols and placebo arms
existed, which might explain the deaths of two patients assigned
to placebo within 40 days of enrolment. There was also no
prespecified power calculation to determine the minimum
number of patients required for adequate statistical power for
efficacy endpoints. In addition, the trial used a non-conventional
DIT dosing regimen. Finally, the EORTC tool to contextualise the
OS data for individual patients was implemented after the trial
was initiated. These data should, therefore, be interpreted with
caution.
CONCLUSION
Nabiximols spray appeared tolerable, and personalised dosing was
feasible in this GBM patient population. No new safety concerns
were identified, and there was no evidence to suggest an effect of
nabiximols on the PK of TMZ. The observed survival differences
should be interpreted with caution and justify further exploration
in an adequately powered randomised controlled trial.
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